



## Equillium to Present at Two Upcoming Investor Conferences

11/9/2021

LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in fireside chat presentations at the Stifel 2021 Virtual Healthcare Conference and the Jefferies Virtual London Healthcare Conference.

Management will provide a high-level overview of itolizumab's mechanism of action and review each of Equillium's ongoing clinical programs, as well as data recently presented at ACR, ASN & ACAAI. Members of Equillium's leadership team will be available for one-on-one meetings during both conferences.

---

Conference:	Stifel 2021 Virtual Healthcare Conference
Location:	Live Virtual Webcast on corporate website
Date:	Tuesday, November 16, 2021
Time:	12:20 PM Pacific Time   3:20 PM Pacific Time

---

Conference:	Jefferies Virtual London Healthcare Conference
Location:	Recorded Virtual Webcast on corporate website
Date:	Thursday, November 18, 2021
Time:	12:00 AM Pacific Time   3:00 AM Eastern Time

Webcast access for both presentations will be available on the "Events & Presentations" section of the Company's website at <https://ir.equilliumbio.com/events-and-presentations>. An archived replay of both conferences will be available for 90 days.

### About Equillium

Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel



products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.

For more information, visit [www.equilliumbio.com](http://www.equilliumbio.com).

## Investor Contact

Michael Moore

Vice President, Investor Relations & Corporate Communications

619-302-4431

[ir@equilliumbio.com](mailto:ir@equilliumbio.com)

## Media Contacts

Aljanae Reynolds

Wheelhouse Life Science Advisors

[areynolds@wheelhousesa.com](mailto:areynolds@wheelhousesa.com)

Source: Equillium, Inc.